Dyax’s HAE Candidate Meets Clinical Endpoints In Phase III Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
With the completion of Phase III testing, Dyax plans to submit final piece of rolling BLA for DX-88 in early fourth quarter.
You may also be interested in...
Dyax’s Acute HAE Candidate Faces Efficacy And Risk Hurdles At Panel Review
Firm is presenting a risk management plan addressing hypersensitivity and anaphylaxis, but efficacy results for Kalbitor (ecallantide) will also be a key discussion topic.
Dyax’s Acute HAE Candidate Faces Efficacy And Risk Hurdles At Panel Review
Firm is presenting a risk management plan addressing hypersensitivity and anaphylaxis, but efficacy results for Kalbitor (ecallantide) will also be a key discussion topic.
Dyax Completes Rolling BLA For HAE Candidate DX-88
Company seeks priority review, which if granted could set an FDA action date in March.